Insulin Resistance - Pipeline Review, H2 2019

Insulin Resistance - Pipeline Review, H2 2019



Pharmaceutical and Healthcare disease pipeline guide Insulin Resistance - Pipeline Review, H2 2019, provides an overview of the Insulin Resistance (Metabolic Disorders) pipeline landscape.

Insulin resistance (IR) is a condition in which the bodys cells become resistant to the effects of insulin. This occurs when insulin levels are sufficiently high over a prolonged period of time causing the bodys own sensitivity to the hormone to be reduced. Symptoms include lethargy, hunger, difficulty concentrating and high blood pressure. Predisposing factors include obesity and hypertension.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Insulin Resistance - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Insulin Resistance (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Insulin Resistance (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Insulin Resistance and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 7 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Insulin Resistance (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Insulin Resistance (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Insulin Resistance (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Insulin Resistance (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Insulin Resistance (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Insulin Resistance (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insulin Resistance (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insulin Resistance (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Introduction
Global Markets Direct Report Coverage
Insulin Resistance - Overview
Insulin Resistance - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Insulin Resistance - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Insulin Resistance - Companies Involved in Therapeutics Development
F. Hoffmann-La Roche Ltd
Lixte Biotechnology Holdings Inc
NorthSea Therapeutics BV
Pfizer Inc
Recursion Pharmaceuticals Inc
Insulin Resistance - Drug Profiles
AZP-3404 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CDN-1163 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
englerin A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FC-98 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fusion Proteins to Target hOGG1 for Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
icosabutate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Revatio - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-7992 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Atherosclerosis and Insulin Resistance - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit AMPD2 for Hypertension and Metabolic Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Immunology, Metabolic Disorders and Musculoskeletal Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Inherited Insulin Resistance Syndrome - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SYM-401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TM-25659 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Insulin Resistance - Dormant Projects
Insulin Resistance - Product Development Milestones
Featured News & Press Releases
Mar 21, 2019: Alize Pharma3 to present data from its AZP-3404program in syndromes of severe insulin resistance at ENDO2019
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables


Number of Products under Development for Insulin Resistance, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Insulin Resistance - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Insulin Resistance - Pipeline by Lixte Biotechnology Holdings Inc, H2 2019
Insulin Resistance - Pipeline by NorthSea Therapeutics BV, H2 2019
Insulin Resistance - Pipeline by Pfizer Inc, H2 2019
Insulin Resistance - Pipeline by Recursion Pharmaceuticals Inc, H2 2019
Insulin Resistance - Dormant Projects, H2 2019
Insulin Resistance - Dormant Projects, H2 2019 (Contd..1), H2 2019

List Of Figures


Number of Products under Development for Insulin Resistance, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

Hyperinsulinemia - Pipeline Review, H2 2019

Hyperinsulinemia - Pipeline Review, H2 2019latest Pharmaceutical and Healthcare disease pipeline guide Hyperinsulinemia - Pipeline Review, H2 2019, provides an overview of the Hyperinsulinemia (Metabolic Disorders) pipeline landscape.Hyperinsulinemia is a

USD 2000 View Report

Congenital Hyperinsulinism Market Insights, Epidemiology and Market Forecast-2028

DelveInsights Batten Disease- Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Batten Disease

USD 6250 View Report

Insulin Resistance - Market Insight, Epidemiology and Market Forecast - 2028

Insulin Resistance - Market Insight, Epidemiology and Market Forecast - 2028 report provides a detailed analysis of the Insulin Resistance epidemiology and market outlook for the 7MM.Markets

USD 6250 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available